OriC322 / Oricell - LARVOL DELTA

GPRC5D and BCMA bi-specific CAR-T: Ex vivo study to simulate early to late-line multiple myeloma (MM) with elevated soluble BCMA. (ASCO 2025) - "The pre-clinical data demonstrated that the bi-specific CAR-T not only outperformed in targeting MM cells mimicking early or middle lines but also reduced the incidence of antigen-negative escape. By enhancing sensitivity and leveraging unique epitopes, the bi-CAR-T maintained robust efficacy in late-line MM models. Future clinical studies will be conducted to validate the safety and efficacy in treating high-risk MM patients."

IO biomarker • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology

GPRC5D and BCMA bi-specific CAR-T: Optimized CAR design to mitigate antigen escape and elicit deep and durable response in heterogeneous multiple myeloma (AACR 2025) - "The pre-clinical data of GPRC5D and BCMA bi-specific CAR-T exhibited superior anti-tumor efficacy and persistence, mitigated Ag escape and preserved potency with shedding BCMA. Our findings provide support for the clinical investigation of the bi-specific CAR-T as a therapeutic approach to broadly and deeply deplete heterogenetic MM cell clones and subsets, potentially leading to durable responses in both newly diagnosed and R/R MM patients."

Heterogeneity • IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology